Devineni D, Polidori D. Clinical pharmacokinetic, pharmacodynamic, and drug–drug interaction profile of canagliflozin, a sodium-glucose co-transporter 2 inhibitor. Clin Pharmacokinet. 2015;54:1027–41.

Article  CAS  PubMed  Google Scholar 

Hammad RW, Sanad RA-B, Abdelmalak NS, Latif R. Architecting novel multilayer nanosponges for co-administration of two drugs managing high-risk type II diabetes mellitus patients suffering from cardiovascular diseases. Int J Biol Macromol. 2022;220:1429–43.

Article  CAS  PubMed  Google Scholar 

L.L.C. Johnson & Johnson Pharmaceutical Research and Development, JNJ-28431754 (Single escalating oral doses combination drug study). 2019.

Wiviott SD, Raz I, Bonaca MP, Mosenzon O, Kato ET, Cahn A, Silverman MG, Zelniker TA, Kuder JF, Murphy SA, Bhatt DL, Leiter LA, McGuire DK, Wilding JPH, Ruff CT, Gause-Nilsson IAM, Fredriksson M, Johansson PA, Langkilde A-M, Sabatine MS. Dapagliflozin and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2018;380:347–57.

Article  PubMed  Google Scholar 

Birnbaum Y, Bajaj M, Yang HC, Ye Y. Combined SGLT2 and DPP4 inhibition reduces the activation of the Nlrp3/ASC inflammasome and attenuates the development of diabetic nephropathy in mice with type 2 diabetes. Cardiovasc Drugs Ther. 2018;32:135–45.

Article  CAS  PubMed  Google Scholar 

Solomon SD, McMurray JJ, Claggett B, de Boer RA, DeMets D, Hernandez AF, Inzucchi SE, Kosiborod MN, Lam CS, Martinez F, Shah SJ. Dapagliflozin in heart failure with mildly reduced or preserved ejection fraction. New England J Med. 2022;387:1089–98.

Margulies KB. Delivering progress in heart failure with preserved ejection fraction. N Engl J Med. 2022;387:1138–40.

Article  PubMed  Google Scholar 

Mohamed IN, Sarhan NR, Eladl MA, El-Remessy AB, El-Sherbiny M. Deletion of thioredoxin-interacting protein ameliorates high fat diet-induced non-alcoholic steatohepatitis through modulation of Toll-like receptor 2-NLRP3-inflammasome axis: histological and immunohistochemical study. Acta Histochem. 2018;120:242–54.

Article  CAS  PubMed  Google Scholar 

Simes BC, MacGregor GG. Sodium-glucose cotransporter-2 (SGLT2) inhibitors: a clinician’s guide. Diabetes, metabolic syndrome and obesity: targets and therapy. 2019;12:2125.

Article  CAS  PubMed  Google Scholar 

Toyoda AKF, Kobayashi M. Tofogliflozin, a SGLT2 inhibitor, improves diabetic ocular complications in spontaneously diabetic Torii rats. Diabetes Updates. 2019.

Garofalo C, Borrelli S, Liberti ME, Andreucci M, Conte G, Minutolo R, Provenzano M, De Nicola L. SGLT2 inhibitors: nephroprotective efficacy and side effects. Medicina. 2019;55:268.

Article  PubMed  PubMed Central  Google Scholar 

Damiani G, Loite U, Ramoni S, Marzano AV. Possible new inflammatory side-effect of SGLT2-inhibitors: fixed drug eruption. J Diabetes Complications. 2016;30:1530–1.

Article  PubMed  Google Scholar 

Liu J, Tian J, Sodhi K, Shapiro JI. The Na/K-ATPase signaling and SGLT2 inhibitor-mediated cardiorenal protection: a crossed road? J Membr Biol. 2021;254:513–29.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Ikeda H, Fukushige Y, Matsubara T, Inenaga M, Kawahara M, Yukawa M, Fujisawa M, Yukawa E, Aki H. Improving water solubility of nateglinide by complexation of β-cyclodextrin. J Therm Anal Calorim. 2016;123:1847–50.

Article  CAS  Google Scholar 

Zhang Y, Harker AH, Luo CJ, Parhizkar M, Edirisinghe M. Co-delivery of saxagliptin and dapagliflozin by electrosprayed trilayer poly (D, l-lactide-co-glycolide) nanoparticles for controlled drug delivery. Intern J Pharma. 2022;628:122279.

Kazi M, Alqahtani A, Ahmad A, Noman OM, Aldughaim MS, Alqahtani AS, Alanazi FK. Development and optimization of sitagliptin and dapagliflozin loaded oral self-nanoemulsifying formulation against type 2 diabetes mellitus. Drug Delivery. 2021;28:100–14.

Article  CAS  PubMed  Google Scholar 

Okuyama H, Hamazaki T, Hama R, Ogushi Y, Kobayashi T, Ohara N, Uchino H. A critical review of the consensus statement from the European Atherosclerosis Society Consensus Panel 2017. Pharmacology. 2018;101:184–218.

Article  CAS  PubMed  Google Scholar 

Health N. The Effect of SGLT-2I on advanced glycation end products. 2020.

Sanofi. SAR439954 (study to assess the intestinal, metabolic and cardiovascular effects of SAR439954 treatment with GLP-1 agonist). 2021.

Ingelheim B. Post-authorization safety study in type 2 diabetic patients in Saudi Arabia treated with empagliflozin to assess the incidence of severe complications. 2022.

Ingelheim B. Study to test whether BI 685509 alone or in combination with GLP-1 agonist have T2DM and hiypertension International Committee of Medical Journal Editors and the World Health Organization ICTRP, 15 study locations. 2022.

Novartis. Assess the effect of LIK066 compared to empagliflozin in T2DM.

Pharma D. Study to evaluate drug-drug interaction of DWP16001 in combination with GLP-1 agonist (phase 1 study). 2022.

Pharma I. Study to evaluate the safety and efficacy of lanifibranor alone and in combination with the IVA337 (SGLT-2I) T2DM. 2022.

W.f.u.h. Sciences. GLP-1 agonist and treatment with intranasal SGLT-2I. 2022;(IRB00075).

Patorno E, Pawar A, Franklin JM, Najafzadeh M, Déruaz-Luyet A, Brodovicz KG, Sambevski S, Bessette LG, Santiago Ortiz AJ, Kulldorff M, Schneeweiss S. Empagliflozin and the risk of heart failure hospitalization in routine clinical care. Circulation. 2019;139:2822–30.

Breder I, Cunha Breder J, Bonilha I, Munhoz DB, Medorima ST, Oliveira DC, Carmo HR, Moreira C, Kontush A, Zimetti F, Zanotti I. Rationale and design of the expanded combination of evolocumab plus empagliflozin in diabetes: EXCEED-BHS3 trial. Ther Adv Chronic Dis. 2020;11:2040622320959248.

H.K.C.s. Hospital, Prospective cohort study of children with GSD1b receiving empagliflozin in: H.K.C.s. hospital (Ed.) Hong Kong, 2021.

P. Children’s Memorial Health Institute, Safety and efficacy of empagliflozin in GSD1b patients with neutropenia (EMPAtia). Children’s Memorial Health Institute, Poland. 2021.

Angsantikul P. Novel pre-coital, non-hormonal multipurpose prevention technology (MPT). Population Council. 2022.

Shiyan S, Suryani RP, Mulyani LN, Pratiwi G. Stability study of super saturable catechin-self nano emulsifying drug delivery system as antidiabetic therapy. Biointerface Res Appl Chem. 2022;12:5811–20.

CAS  Google Scholar 

Singh D, Bedi N, Tiwary AK, Kurmi BD, Bhattacharya S. Natural bio functional lipids containing solid self-microemulsifying drug delivery system of canagliflozin for synergistic prevention of type 2 diabetes mellitus. Journal of Drug Delivery Science and Technology. 2022;69: 103138.

Article  CAS  Google Scholar 

Scholar G. Diabetes drug delivery. 2021.

Supakul S, Nishikawa Y, Teramura M, Takase T. Short-term treatment with empagliflozin resulted in dehydration and cardiac arrest in an elderly patient with specific complications: a case report and literature review. Medicina (Kaunas) 2022;58.

Leng W, Wu M, Pan H, Lei X, Chen L, Wu Q, Ouyang X, Liang Z. The SGLT2 inhibitor dapagliflozin attenuates the activity of ROS-NLRP3 inflammasome axis in steatohepatitis with diabetes mellitus. Ann Transl Med. 2019;7:429.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Dhillon S. Dapagliflozin: a review in type 2 diabetes. Drugs. 2019;79:1135–46.

Article  CAS  PubMed  PubMed Central  Google Scholar